BiomX Inc

For the period ended Sep 30, 2024. Filed Nov 14, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 14, 2024

HLSQ$0.07-37.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations (unaudited)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

	Three Months Ended September 30,		Nine Months Ended September 30,
	2024	2023	2024	2023
Research and development (“R&D”) expenses, net	7,279	5,641	18,281	14,023
General and administrative expenses	3,248	2,154	8,756	6,053
Goodwill impairment	801	-	801	-
Operating loss	11,328	7,795	27,838	20,076
Other income	(84)	(89)	(2,189)	(270)
Interest expenses	5	574	868	1,884
Income from change in fair value of Private Placement Warrants	(20,559)	-	(24,417)	-
Finance expense (income), net	(332)	(382)	1,104	(1,034)
Loss (income) before tax	(9,642)	7,898	3,204	20,656
Tax expenses	-	8	10	22
Net loss (income)	(9,642)	7,906	3,214	20,678
Basic loss (earnings) per share of Common Stock (*)	(0.31)	1.30	0.32	4.29
Diluted loss (earnings) per share of Common Stock (*)	(0.31)	1.30	2.45	4.29
Weighted average number of shares used in computing basic loss (earnings) per share of Common Stock	16,366,122	6,058,774	9,944,267	4,819,658
Weighted average number of shares used in computing diluted loss (earnings) per share of Common Stock	16,387,633	6,058,774	11,294,880	4,819,658

(*)	All share amounts have been retroactively adjusted to reflect a 1-for-10 reverse share split as discussed in Note 10A.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE

PREFERRED SHARES AND IN STOCKHOLDERS’ EQUITY (CAPITAL DEFICIENCY)

Redeemable Convertible Preferred Shares · Redeemable Convertible Preferred Shares · Common Stock (****) · Additional Paid-in · Accumulated · Total Stockholders’ Equity (Capital
	Shares	Amount	Shares	Amount	Shares	Amount	Capital	Deficit	Deficiency)
Balance as of January 1, 2024	-	-	-	-	4,723,320	3	166,048	(162,970)	3,081
Issuance of Common Stock, Merger Warrants and Redeemable Convertible Preferred Shares upon the APT acquisition, net of issuance cost (***)	40,470	12,561	-	-	916,497	1	3,227	-	3,228
Exercise of Pre-Funded Warrants into shares of Common Stock (**)			-	-	477,827	*	5	-	5
Issuance of Common Stock under At the Market Sales Agreement, net of $1 issuance costs (**)			-	-	7,518	*	19	-	19
Stock-based compensation expenses			-	-	-	-	909	-	909
Issuance of Redeemable Convertible Preferred Shares upon March 2024 PIPE, net of issuance costs (**)	216,417	19,859	-	-	-	-	541		541
Net loss			-	-	-	-		(17,327)	(17,327)
Balance as of March 31, 2024	256,887	32,420	-	-	6,125,162	4	170,749	(180,297)	(9,544)
Exercise of Pre-Funded Warrants into shares of Common Stock (**)			-	-	980,811	1	-	-	1
Stock-based compensation expenses			-	-	-		77	-	77
Reclassification of Redeemable convertible preferred Shares to equity	(256,887)	(32,420)	256,887	32,420	-	-	-	-	32,420
Net income			-	-				4,471	4,471
Balance as of June 30, 2024	-	-	256,887	32,420	7,105,973	5	170,826	(175,826)	27,425
Redeemable Convertible Preferred Shares conversion into shares of Common Stock			(109,152)	(13,775)	10,915,200	1	13,774		-
Issuance of Common Stock upon restricted stock units (“RSU”) vesting	-	-			155,429	*	-	-	*
Stock-based compensation expenses			-	-	-	-	829	-	829
Net income			-	-	-	-	-	9,642	9,642
Balance as of September 30, 2024	-	-	147,735	18,645	18,176,602	6	185,429	(166,184)	37,896

(*)	Less than $1.
(**)	See Note 10A.
(***)	See Note 1D.
(****)	All share amounts have been retroactively adjusted to reflect a 1-for-10 reverse share split as discussed in Note 10A.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE

PREFERRED SHARES AND IN STOCKHOLDERS’ EQUITY (CAPITAL DEFICIENCY)

Common Stock (***) · Additional Paid-in · Accumulated · Total Stockholders’
	Shares	Amount	Capital	Deficit	Equity
Balance as of January 1, 2023	3,122,987	2	157,838	(136,801)	21,039
Issuance of Common Stock and warrants under February 2023 PIPE, net of $176 issuance costs (**)	319,950	*	1,293	-	1,293
Stock-based compensation expenses	-	-	175	-	175
Net loss	-	-	-	(6,361)	(6,361)
Balance as of March 31, 2023	3,442,937	2	159,306	(143,162)	16,146
Issuance of Common Stock and warrants under February 2023 PIPE, net of $157 issuance costs (**)	1,279,796	1	5,858		5,859
Stock-based compensation expenses	-	-	271		271
Net loss				(6,411)	(6,411)
Balance as of June 30, 2023	4,722,733	3	165,435	(149,573)	15,865
Stock-based compensation expenses	-	-	195	-	195
Net loss	-	-	-	(7,906)	(7,906)
Balance as of September 30, 2023	4,722,733	3	165,630	(157,479)	8,154

(*)	Less than $1.

(**)	See Note 10A.
(***)	All share amounts have been retroactively adjusted to reflect a 1-for-10 reverse share split as discussed in Note 10A.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.